



Efficacy of Different Antiemetics with Different Mechanism of Action on Xylazine Induced Emesis in Cats

Saeed Kolahian

Abstract

Xylazine hydrochloride, α_2 adrenoceptor agonist, is an analgesic, sedative, tranquilizer, and muscle relaxant agent in veterinary medicine which is mostly used as in pre-anesthesia in veterinary medicine. One of the main adverse effects of xylazine which limits application of this medication in small animal veterinary practice (mostly in cats) is nausea and vomiting which can end up with aspiration pneumonia. In this review, we will discuss the efficacy of prophylactic administration of different antiemetics with different mechanism of action in preventing vomiting in cats treated with xylazine hydrochloride. All medications such as acepromazine, promethazine, metoclopramide, ondansetron, dexamethasone, maropitant and vitamin B6 have been shown to have antiemetic efficacy on xylazine induced emesis in cats. These mentioned medications have different antiemetic mechanism of actions. It can be concluded that all these medications not only inhibit α_2 adrenoceptor but also may exert their antiemetic effects directly on nucleus tractus solitarius and vomiting center.

Keywords: Emesis, Cat, Xylazine, Antiemetic

Introduction

Xylazine hydrochloride is an analgesic, sedative, tranquilizer, and muscle relaxant agent in veterinary medicine.¹ Xylazine-induced emesis, mediated by α_2 adrenoceptor placed in chemoreceptor trigger zone (CTZ) of the area postrema, occurs frequently in cats, and hence increases the risk of aspiration pneumonia.²⁻⁴ Using an α_2 adrenoceptor antagonist such as yohimbine, tolazoline, and phentolamine inhibits xylazine-induced emesis in cats but also prevents its sedative effects in these animals.⁵⁻⁷ On the other hand, it is well-known that the medulla oblongata has substantial neuronal activity in regulation of the emetic reflex⁸ and nucleus tractus solitarius (NTS) is richly supplied with many kinds of vomiting-related neurotransmitters and neuromodulators, such as opioid, gamma-amino butyric acid (GABA), adrenaline, noradrenaline, dopamine, serotonin, histamine and substance P.^{9, 10} In this review, we will discuss these recent findings on the efficacy of prophylactic administration of different antiemetics

which are acting via different mechanisms (including neurotransmitters and receptors), in preventing vomiting in cats treated with xylazine hydrochloride.

Introduction of Xylazine

Xylazine hydrochloride was synthesized in Germany in 1962 and was the first α_2 adrenergic agonist to be used as sedative, tranquilizer, analgesic and muscle relaxant by veterinarian.¹ The sedative effect is because of central α_2 adrenergic agonist action.¹¹ Enhancement of the analgesic response may also occur as the result synergistic interaction between α_2 adrenergic agonist and opiates in the spinal cord.¹² It has more, better and longer visceral analgesic effect than butorphanol, meperidine and pentazocine.¹³ Xylazine relaxes muscles by inhibition of interneuronal transmission of impulses at the central level of the CNS.¹⁴ All these beneficial effects of xylazine make this medication significantly more valuable than other sedatives and tranquilizers like benzodiazepines and phenothiazines for veterinary use. One of the main side effect of xylazine in small animal practice (especially in cats and less important in dogs) is nausea and vomiting. Xylazine causes emesis by direct effect on α_2 and opiate receptors placed in CTZ of the area postrema. This effect can be very dangerous in small animal practice

Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Iran.

Address all correspondence to Dr. Saeed kolahian (DVM, PhD),
E-mail: skolahian@tabrizu.ac.ir

because of increasing the risk of aspiration pneumonia.²⁻
⁴ New generation of α_2 agonists like detomidine and medetomidine is now available in market with less emetic effect. But clarification of inhibitory efficacy of different antiemetics which are acting via different receptors than α_2 receptors, can explain interaction of different receptors in vomiting centers which is so interesting in basic and clinical pharmacology of emesis.

Nausea and vomiting

Vomiting is the forceful expulsion of the stomach contents through the mouth and sometimes the nose.¹⁵ Variety conditions like gastritis or poisoning can cause vomiting. Sometimes vomiting is a non-specific response of some disorders ranging from brain tumors and elevated intracranial pressure to overexposure to ionizing radiation. There are various sources of input to the vomiting center: 1) The chemoreceptor trigger zone at the base of the fourth ventricle, enriched with numerous dopamine D2 receptors, serotonin 5-HT₃ receptors, opioid receptors, acetylcholine receptors, and receptors for substance P. 2) The vestibular system, which transmit information from ear to the brain via cranial nerve VIII (vestibulocochlear nerve), and plays a major role in motion sickness, and is rich in muscarinic receptors and histamine H₁ receptors. 3) The Cranial nerve X (vagus nerve) is activated by pharynx irritation, leading to a gag reflex. 4) The Vagal and enteric nervous system send information regarding the state of the gastrointestinal system. 5) The CNS mediates vomiting that arises from psychiatric disorders and stressful conditions from higher brain centers.^{16, 17} Vomiting can be very dangerous if the gastric content enters the respiratory system. Under normal conditions the gag and coughing reflexes prevent this from occurring; however these protective reflexes are abolished in animals under the influences of certain substances such as anesthesia which can be end up with aspiration pneumonia.

Xylazine induced emesis in cats

CTZ of cat is highly enriched in α_2 adrenoreceptors which make this animal sensitive to α agonist like adrenalin and noradrenalin which were produced in stress condition or medication like α_2 agonists such as xylazine. Xylazine induced emesis is mediated by α_2 adrenoreceptor placed in CTZ of the area postrema.^{2,3}

Antiemetics

An antiemetic is a medication that is effective against nausea and vomiting. Antiemetics are used to prevent or treat motion sickness and the side effects of opioid analgesics, general anesthetics, chemotherapy directed against cancer and any other medications induced

emesis like xylazine.¹⁸ There are various antiemetics in practice which they have different mechanism of action and their effect is mediated via different receptors. Antiemetics include: 1) 5-HT₃ receptor antagonists: these block serotonin receptors in the central nervous system and gastrointestinal tract. They include: a) Dolasetron b) Granisetron c) Ondansetron d) Tropisetron e) Palonosetron f) Mirtazapine. 2) Dopamine antagonists block dopamine receptors in the brain and are used to treat nausea and vomiting associated with neoplastic disease, radiation sickness, opioids, cytotoxic drugs and general anesthetics. They include: a) Domperidone, b) Olanzapine, c) Droperidol, d) haloperidol, e) chlorpromazine, f) promethazine, g) prochlorperazine. Some of these drugs are limited in their usefulness by their extra-pyramidal and sedative side-effects. h) Metoclopramide as a pro-kinetic drug acts on the GI tract, and is thus useful in gastrointestinal disease 3) neurokinin-1 (NK-1) receptor antagonist which include a) Aprepitant, b) Maropitant and c) Casopitant. 4) Antihistamines (H1 histamine receptor antagonists), with an expand effectiveness act in various conditions, including motion sickness, morning sickness in pregnancy, and opioid nausea. They include a) Cyclizine, b) Diphenhydramine, c) Dimenhydrinate, d) Doxylamine, e) Meclozine, f) Promethazine and g) Hydroxyzine. 5) Benzodiazepines which include a) Midazolam and b) Lorazepam which mostly effective in psychotic nausea and vomiting 7) Anticholinergics like a) Hyoscine (also known as scopolamine) 8) Steroids like a) Dexamethasone 9) Other miscellaneous antiemetics like a) Trimethobenzamide (thought to work on the CTZ), and b) Ginger (contains 5HT3 antagonists gingerols and shogaols).¹⁴

In this review, we will discuss these recent findings in which we will focus on the efficacy of prophylactic administration of different antiemetics which are acting via different mechanism (including neurotransmitters and receptors), in preventing vomiting in cats treated with xylazine hydrochloride.

Acepromazine

Acepromazine or acetylpromazine is a phenothiazine derivative antipsychotic drug. It is frequently used in animals as a sedative and antiemetic. Hikasa et al. have shown that acepromazine can inhibit emesis in cat via acting centrally on chemoreceptor trigger zone and vomiting center in the medulla oblongata as well as increasing gastric tone and peristalsis.⁴

Topal and Gul studied the effects of dexamethasone, metoclopramide and acepromazine on xylazine induced emesis in Cats. They injected antiemetic drugs in semitendinous muscle of one leg. Acepromazine was administered with relatively high dosage of 0.1 mg/kg. One hour later, each cat received xylazine (2 mg/kg, intramuscularly (IM)) in the semitendinous muscle of the other leg. They reported that acepromazine couldn't

reduce incidence of xylazine-induced emesis, but it was able to significantly increase latency time of emesis (time until onset of the first emetic episode). Furthermore, acepromazine at the studied dose did not alter the recumbency period induced by xylazine. The cats also experienced prolonged sedation period after administration of xylazine.¹⁹ It has to be mentioned that the dose of xylazine in this study was higher than the other studies mentioned in this review.

Promethazine

It has been shown that prior treatment of cats with promethazine is effective in reducing the frequency of xylazine-induced emesis. 3 dosages of promethazine HCl (1, 2 and 4 mg/kg of body weight, IM) was injected an hour before administration of xylazine (0.66 mg/kg, IM) with one week intervals. Prior treatment with promethazine at dosages 2 and 4 mg/kg significantly reduced the number of episodes of emesis induced by xylazine. Promethazine did not alter the time until onset of the first emetic episode as well as the time to onset of sedation in xylazine injected cats. It is assumed that promethazine exerts its antiemetic action on xylazine induced emesis via inhibiting histamine and dopamine receptors of NTS rather than inhibition of α_2 adrenoceptors.²⁰

Metoclopramide

Dopamine stimulates the medullary CTZ, producing nausea and vomiting. It has been shown that metoclopramide inhibits xylazine induced emesis in cats.²¹ Five dosages of metoclopramide HCl (0.2, 0.4, 0.6, 0.8 and 1 mg/kg of body weight, IM) was evaluated against saline (0.9% NaCl) solution. Prior treatment with metoclopramide at any of mentioned dosages did not significantly alter the latency time of emesis in cats sedated with xylazine hydrochloride. But each dosage of metoclopramide significantly reduced the number of episodes of emesis in these cats. Results showed that 1 mg/kg of metoclopramide injected prior to administration of xylazine significantly reduced the time until onset of sedation in cats. Because of its antagonistic effect on dopamine and serotonin receptors, metoclopramide may complete its antiemetic action in xylazine induced emesis via inhibiting dopamine and serotonin (5HT₃) receptors in the bilateral NTS in this nervous pathway.

Ondansetron

5-HT₃ receptors are found pre- and postsynaptically. Release of several neurotransmitters such as dopamine, cholecystokinin, GABA, substance P and acetylcholine is regulated by their activation.²² 5-HT₃ antagonists may have antiemetic effects in cats sedated with xylazine. It has been shown that ondansetron at dosages

of 0.2, 0.4 and 0.8 mg/kg injected prior to administration of xylazine significantly reduced the number of episodes of emesis. Ondansetron may not inhibit α_2 adrenoceptors for its antiemetic action; rather it may exert its antiemetic action on xylazine induced emesis indirectly on vomiting center in medulla oblongata and block vomiting pathways via antagonizing 5-HT₃ receptors of the area postrema.²³

Dexamethasone

Several studies have suggested that glucocorticoids, such as dexamethasone, may be involved in the control of xylazine induced emesis.^{19, 24, 25} After first report of dexamethasone as an effective antiemetic in cancer patients receiving chemotherapy²⁶ several studies have documented that dexamethasone is effective in preventing emesis caused by chemotherapy in humans,²⁷⁻²⁹ cats,³⁰ dogs,³¹ ferrets,^{32, 33} and pigeons³⁴. In a study by Topal and Gul, it was shown that Dexamethasone (4 mg/kg, IM), prevented xylazine (2 mg/kg, IM) induced vomiting in five of ten cats. Pre-treatment with dexamethasone also reduced incidence of vomiting induced by xylazine in the other five cats with no significant change in the time until onset of the first emetic episode.¹⁹ This finding is in agreement with findings of Ho et al. (2001) which showed prior IM treatment with dexamethasone (4 or 8 mg/kg) significantly reduces the frequency of xylazine induced emesis. But they stated that dexamethasone significantly delays latency time of vomiting after xylazine injection in cats. It may be due to lower dose of xylazine (0.66 mg/kg) which has been used in their study. However, dexamethasone doesn't significantly change the time until onset of sedation after administration of xylazine.²⁴ Several authors have hypothesized that the bilateral NTS may be the common final pathway that links to the vomiting center.³⁵ Moreover, large numbers of glucocorticoid receptors are in the bilateral NTS.³⁶ Dexamethasone could ameliorate vomiting response through its action on glucocorticoid receptors in the bilateral NTS.²⁵

Maropitant

Maropitant was highly effective in preventing motion induced emesis in cats at the dosage of 1 mg/kg. It is a NK-1 receptor antagonist that is well tolerated, safe and possesses excellent anti-emetic properties in cats. Provocative motion sickness needs the vestibular system, the signals from which finally activate brain stem areas involved in emesis including the NTS, the dorsal motor nucleus and an area adjacent to the area postrema.³⁷⁻³⁹ Comparable to other anti-emetic agents, NK-1 receptor antagonists are effective against a wide range of emetogens including radiation, cisplatin, cyclophosphamide, copper sulfate and apomorphine as well as motion-induced emesis.⁴⁰⁻⁴⁵ Such wide spectrum

activity against peripheral and central emetogens suggests that NK-1 receptor antagonists must have a site of action in a final common pathway of the emetic reflex. Maropitant effectively prevented xylazine (0.66 mg/kg) induced emesis in cats when administered at the dosage of 1 mg/kg via the subcutaneous, intravenous or per oral route 2 h before xylazine challenge; it could reduce the mean number of emetic episodes by 76, 100 and 90%, respectively, compared to untreated cats. Hickman et al. concluded that the site of the anti-emetic action of maropitant is most likely to be within the central nervous system.⁴⁶

Vitamin B6

Vitamin B6 is a water-soluble B complex vitamin that is an essential coenzyme in the metabolism of amino acids, carbohydrates, and lipids.⁴⁷ It has been shown that vitamin B6 is an effective therapy for nausea and vomiting of pregnancy in humans.⁴⁸⁻⁵⁰ Vitamin B6 is also commonly used as a first-line therapy for patients who experienced nausea and vomiting during or after chemotherapy,⁵¹ and its safety has been proved when used in appropriate dose.^{52, 53} The results of a recently published study indicated that pretreatment of cats with vitamin B6 at dosages of 5, 10, 20 and 40 mg/kg before injecting xylazine (0.66 mg/kg) could reduce episodes of emesis without any significant change in the time needed for sedation of cats after administration of xylazine.⁵⁴ Vitamin B6 may be used as a prophylactic antiemetic in cats treated with xylazine. As vitamin B6 administration increases central production of GABA,⁵⁵ it may exert its antiemetic action indirectly on vomiting center in medulla oblongata and block vomiting pathways via stimulating GABA receptors of the area postrema. It was shown that GABA receptors are abundant in the area postrema of the cat.⁵⁶ On the other hand, baclofen, a selective GABA_B receptor agonist, has been shown to have direct inhibitory action in dorsal vagal complex (DVC) neurons in morphine-induced emesis in ferrets.¹⁰ DVC in the brainstem regulates the emetic reflex in ferrets⁵⁷ and GABA mediates the inhibitory synaptic currents in these areas.⁵⁸

References

- Greene SA. Pros and cons of using alpha-2 agonists in small animal anesthesia practice. *Anesthesiology* 1999;14(1):10-14.
- Greene SA, Thurmon JC. Xylazine – a review of its pharmacology and use in veterinary medicine. *J Vet Pharmacol Ther* 1988;11(4):295-313.
- Hikasa Y, Takase K, Ogasawara S. Evidence for the involvement of alpha 2-adrenoceptors in the emetic action of xylazine in cats. *Am J Vet Res* 1989;50(8):1348-1351.
- Hikasa Y, Akiba T, Iino Y, et al. Central α -adrenoceptor subtypes involved in the emetic pathway in cats. *Eur J Pharmacol* 1992;229(2):241-251.
- Hikasa Y, Takase K, Saito K, et al. Antagonism of the emetic action of xylazine by α -adrenoceptor blocking agents. *Eur J Pharmacol* 1986;130(3):229-235.
- Hatch RC, Booth NH, Clark JD, et al. Antagonism of xylazine sedation in dogs by 4-aminopyridine and yohimbine. *Am J Vet Res* 1982;43(6):1009-1014.

Conclusion

As discussed briefly, all medications such as acepromazine, promethazine, metoclopramide, ondansetron, dexamethasone and vitamin B6 have been shown to have antiemetic efficacy on xylazine induced emesis in cats. These mentioned medications have different antiemetic mechanism of actions. It can be concluded that all these medications may exert their antiemetic effects directly on NTS and vomiting center (Fig 1).




Figure1. Different antiemetics with different mechanism of actions may exert their antiemetic effects on xylazine induced emesis directly on NTS and vomiting center. "RTs" is abbreviation of "Receptors".

Abbreviations

CTZ: Chemoreceptor Trigger Zone; NTS: Nucleus Tractus Solitarius; GABA: Gamma-Amino Butyric Acid; CNS: Central Nervous System; IM: Intramuscularly; NK-1: neurokinin-1.

Acknowledgment

I am grateful to Dr. Seyed Hosein Jarolmasjed for critical reading of the manuscript and his technical helps.

7. Hsu W, Lu Z. Effect of yohimbine on xylazine-ketamine anesthesia in cats. *J Am Vet Med Assoc* 1984;185(8):886-888.
8. Carpenter DO. Neural mechanisms of emesis. *Can J Physiol Pharmacol* 1990;68(2):230-236.
9. Miller AD, Leslie RA. The area postrema and vomiting. *Front Neuroendocrinol* 1994;15(4):301-320.
10. Suzuki T, Nurrochmad A, Ozaki M, et al. Effect of a selective GABA(B) receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects. *Neuropharmacol* 2005;49(8):1121-1131.
11. McCurnin DM, Bassett JM. *Clinical textbook for veterinary technicians*. 7th ed. Philadelphia: Saunders Co, 2006.
12. Ware TD, Paul D. Cross-tolerance between analgesia produced by xylazine and selective opioid receptor subtype treatments. *Eur J Pharmacol* 2000;389(2):181-185.
13. Muir W, Robertson J. Visceral analgesia: effects of xylazine, butorphanol, meperidine, and pentazocine in horses. *Am J Vet Res* 1985;46(10):2081-2084.
14. Riviere JE, Papich MG. *Veterinary pharmacology and therapeutics*. 9th ed. Wiley-Blackwell, Iowa state university, 2009.
15. Tintinalli and Judith E. *Emergency Medicine: A Comprehensive Study Guide (Emergency Medicine (Tintinalli))*. New York: McGraw-Hill Companies, 2010, p. 830.
16. Hornby PJ. Central neurocircuitry associated with emesis. *Am J Med* 2001;111(8):106-112.
17. Ray AP, Chebolu S, Ramirez J, et al. Ablation of least shrew central neurokinin NK₁ receptors reduces GR73632-induced vomiting. *Behav Neurosci* 2009;123(3):701-706.
18. Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. *Am Fam Physician* 2004;69(5):1169-1174.
19. Topal A, Gül N. Effects of dexamethasone, metoclopramide or acepromazine on emesis in cats sedated with xylazine hydrochloride. *Acta Vet Brno* 2006;75(2):299-303.
20. Kolahian S, Jarolmasjed SH. Antiemetic efficacy of promethazine on xylazine-induced emesis in cats. *Can Vet J* 2012;53(2):193-195.
21. Kolahian S, Jarolmasjed S. Effects of metoclopramide on emesis in cats sedated with xylazine hydrochloride. *J Feline Med Surg* 2010;12(12):899-903.
22. Thompson AJ, Lummis SC. The 5-HT₃ receptor as a therapeutic target. *Expert Opin Ther Targets* 2007;11(4):527-540.
23. Jarolmasjed S, Kolahian S. Effects of ondansetron on xylazine induced emesis in cats. *IJVS* 2010;5(1/2):63-70.
24. Ho CM, Ho ST, Wang JJ, et al. Effects of dexamethasone on emesis in cats sedated with xylazine hydrochloride. *Am J Vet Res* 2001;62(8):1218-1221.
25. Ho CM, Ho ST, Wang JJ, et al. Dexamethasone has a central antiemetic mechanism in decerebrated cats. *Anesth Analg* 2004;99(3):734-739.
26. Aapro MS, Alberts DS. Dexamethasone as an antiemetic in patients treated with cisplatin. *N Engl J Med* 1981;305(9):520.
27. Jones A, Hill A, Cunningham D, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. *Lancet* 1991;338(8765):483-487.
28. Spector JL, Lester EP, Chevlen EM, et al. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy. *Oncologist* 1998;3(6):432-438.
29. Wang JJ, Ho ST, Lee SC, et al. The prophylactic effect of dexamethasone on postoperative nausea and vomiting in women undergoing thyroidectomy: a comparison of droperidol with saline. *Anesth Analg* 1999;89(1):200-203.
30. Rudd JA, Tse JY, Wai MK. Cisplatin-induced emesis in the cat: effect of granisetron and dexamethasone. *Eur J Pharmacol* 2000;391(1):145-150.
31. Fukui H, Yamamoto M. Methotrexate produces delayed emesis in dogs: a potential model of delayed emesis induced by chemotherapy. *Eur J Pharmacol* 1999;372(3):261-267.
32. Hawthorn J, Cunningham D. Dexamethasone can potentiate the anti-emetic action of a 5HT₃ receptor antagonist on cyclophosphamide induced vomiting in the ferret. *Brit J Cancer* 1990;61(1):56-60.
33. Rudd JA, Naylor R. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. *Brit J Pharmacol* 1996;118(2):209-214.
34. Tanihata S, Igarashi H, Suzuki M, et al. Cisplatin-induced early and delayed emesis in the pigeon. *Brit J Pharmacol* 2000;130(1):132-138.
35. Andrews P, Rapeport W, Sanger G. Neuropharmacology of emesis induced by anti-cancer therapy. *Trends Pharmacol Sci* 1988;9(9):334-341.
36. Morimoto M, Morita N, Ozawa H, et al. Distribution of glucocorticoid receptor immunoreactivity and mRNA in the rat brain: an immunohistochemical and in situ hybridization study. *Neurosci Res* 1996;26(3):235-269.
37. Brizzee KR. *The central nervous connections involved in motion induced emesis*. In: Crampton GH (ed) Motion and Space Sickness. Boca Raton, USA: CRC Press, 1990, pp.9-28.
38. Miller AD, Nonaka S, Jakus J. Brain areas essential or non-essential for emesis. *Brain research* 1994;647(2):255-264.
39. Zajonc TP, Roland PS. Vertigo and motion sickness. Part II: Pharmacologic treatment. *Ear Nose and Throat* 2006;85(1):25-35.
40. Bountra C, Bunce K, Dale T, et al. Antiemetic profile of a nonpeptide neurokinin NK₁ receptor antagonist, CP 99994 in ferrets. *Eur J Pharmacol* 1993; 249: R3-R4.
41. Patel L, Lindley C. Aprepitant--a novel NK₁-receptor antagonist. *Expert Opin Pharmacol Ther* 2003;4(12):2279-2296.
42. Benchaoui HA, Cox SR, Schneider RP, et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. *J Vet Pharmacol Ther* 2007;30(4):336-344.
43. De la Puente-Redondo VA, Tilt N, Rowan TG, et al. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. *Am J Vet Res* 2007;68(1):48-56.

44. Sedlacek H, Ramsey D, Boucher J, et al. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. *J Vet Pharmacol Ther* 2008;31(6):533-537.
45. Vail DM, Rodabaugh HS, Conder GA, et al. Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients. *Vet Comp Oncol* 2007;5(1):38-46.
46. Hickman M, Cox S, Mahabir S, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia™) for the prevention of emesis and motion sickness in cats. *J Vet Pharmacol Ther* 2008;31(3):220-229.
47. Briggs GG, Freeman RK and Yaffe SJ. *Drugs in pregnancy and lactation*. 8th ed. Philadelphia: Lippincott Williams and Wilkins, 2008.
48. Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. *Cochrane Database Syst Rev* 2003;4(4).
49. Sahakian V, Rouse D, Sipes S, et al. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. *Obstet and Gynecol* 1991;78(1):33-36.
50. Vutyavanich T, Wongtra-ngan S, Ruangsri R-a. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. *Am J Obstet Gynecol* 1995;173(3):881-884.
51. You Q, Yu H, Wu D, et al. Vitamin B6 points PC6 injection during acupuncture can relieve nausea and vomiting in patients with ovarian cancer. *Int J Gynecol Cancer* 2009;19(4):567-571.
52. Shrim A, Boskovic R, Maltepe C, et al. Pregnancy outcome following use of large doses of vitamin B6 in the first trimester. *J Obstet Gynaecol* 2006;26(8):749-751.
53. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. *Drugs* 2000;59(4):781-800.
54. Jarolmasjed S, Kolahian S. Pretreatment of Cats with Vitamin B6 Reduces Vomiting Episodes Following Xylazine Administration. *IJVS* 2013;8:29-34.
55. McCarty M. High-dose pyridoxine as an 'anti-stress' strategy. *Med hypotheses* 2000;54(5):803-807.
56. Newton BW, Maley BE. A comparison of GABA-and GAD-like immunoreactivity within the area postrema of the rat and cat. *J Comp Neurol* 1987;255(2):208-216.
57. Miller AD. Central mechanisms of vomiting. *Digest Dis Sci* 1999;44(8):39S-43S.
58. Travagli R, Gillis R, Rossiter C, et al. Glutamate and GABA-mediated synaptic currents in neurons of the rat dorsal motor nucleus of the vagus. *Am J Physiol* 1991;260(3):G531-G536.

چکیده

کارائی ضد استفراغ های متفاوت با مکانیسم متفاوت بر استفراغ ناشی از زایلازین هیدروکلراید در گربه

سعید کلاهیان

گروه علوم پایه دانشکده دامپزشکی، دانشگاه تبریز، تبریز، ایران.

زایلازین هیدروکلراید، آگونیست آلفا-۲ آگونیستی، یک داروی ضد درد، مسکن، آرام بخش و شل کننده عضلانی در دامپزشکی می باشد که بیشتر در پیش بیهوشی در دامپزشکی مورد استفاده قرار می گیرد. یکی از مهمترین اثرات جانبی زایلازین تهوع و استفراغ می باشد که استفاده از این دارو را در طب دامهای کوچک به خصوص گربه ها محدود می کند چرا که می تواند این اثر در نهایت به پنومونی استنشاقی منجر گردد. در این مقاله مروری، ما در مورد کارائی تجویز پیش گیرانه ضد استفراغ های مختلف با مکانیسم های اثر مختلف در پیش گیری از استفراغ ناشی از تجویز زایلازین هیدروکلراید در گربه بحث خواهیم کرد. کارائی تمامی داروهای ذکر شده مانند، آسه پرومازین، پرومتازین، متوکلوپرامید، اندانسترون، دکزامتازون، ماروپیتنت و ویتامین ب ۶ در مهار استفراغ ناشی از زایلازین هیدروکلراید در گربه ها مشخص گردیده است. داروهای مذکور دارای مکانیسم اثر ضد استفراغی متفاوتی می باشند. نتیجه گیری حاصل از این مقاله مروری نشان می دهد که نه تنها هیچ یک از داروهای مذکور اثر مهار استفراغ ناشی از زایلازین در گربه را با مهار گیرنده های آلفا ۲ به جای نمی گذارند بلکه این اثر ضد استفراغی آنها ناشی از اثر مستقیم آنها در هسته مسیر منزوی و مرکز استفراغ می باشد.

کلید واژگان: کارائی، استفراغ، گربه، زایلازین، ضد استفراغ

